PropertyValue
is ?:annotates of
?:authorAffiliation
  • [\'Experimental Medicine Unit, de Duve Institute, Université Catholique de Louvain, 74 Avenue Hippocrate, 1200, Brussels, Belgium.\', \'Department of Laboratory Medicine, Cliniques Universitaires Saint-Luc, Brussels, Belgium.\', \'Institut de Recherche Expérimentale et Clinique (IREC), Université Catholique de Louvain, Brussels, Belgium.\', \'Virology Unit, de Duve Institute, Université Catholique de Louvain, Brussels, Belgium.\', \'Department of Gynecology-Andrology, Cliniques Universitaires Saint-Luc, Université Catholique de Louvain, Brussels, Belgium.\', \'Tumor Infiltrating Lymphocytes Unit, de Duve Institute, Université Catholique de Louvain, Brussels, Belgium.\', \'Pôle de Recherche Cardiovasculaire (CARD), Institut de Recherche Expérimentale et Clinique (IREC), Université Catholique de Louvain (UCLouvain), Brussels, Belgium.\', \'Cardiovascular Intensive Care, Cliniques Universitaires Saint-Luc, Brussels, Belgium.\', \'Intensive Care, Cliniques Universitaires Saint-Luc, Brussels, Belgium.\', \'Pôle de Recherche Pharmacologie et de Thérapeutique (FATH), Institut de Recherche Expérimentale et Clinique (IREC), Université Catholique de Louvain (UCLouvain), Brussels, Belgium.\', \'Department of Internal Medicine and Infectious Diseases, Cliniques Universitaires Saint-Luc, Brussels, Belgium.\', \'Genetics of Autoimmune Diseases and Cancer, de Duve Institute, Université Catholique de Louvain, Brussels, Belgium.\', \'Experimental Medicine Unit, de Duve Institute, Université Catholique de Louvain, 74 Avenue Hippocrate, 1200, Brussels, Belgium. laure.dumoutier@uclouvain.be.\']
?:citedBy
  • -1
?:creator
?:doi
  • 10.1038/s41598-022-06038-5
?:doi
?:hasPublicationType
?:journal
  • Scientific reports
is ?:pmid of
?:pmid
?:pmid
  • 35136139
?:publication_isRelatedTo_Disease
?:rankingScore_SJR
  • 1.533
?:rankingScore_hIndex
  • 122
is ?:relation_isRelatedTo_publication of
?:title
  • Development of SARS-CoV2 humoral response including neutralizing antibodies is not sufficient to protect patients against fatal infection.
?:type
?:year
  • 2022

Metadata

Anon_0  
<http://www.w3.org/1999/02/22-rdf-syntax-ns#type> <http://purl.org/net/provenance/ns#DataItem>
<http://www.w3.org/1999/02/22-rdf-syntax-ns#type> <http://www.w3.org/2004/03/trix/rdfg-1/Graph>
<http://xmlns.com/foaf/0.1/primaryTopic> <https://research.tib.eu/covid-19/entity/35136139>
<http://xmlns.com/foaf/0.1/topic> Anon_0
<http://www.ontologydesignpatterns.org/cp/owl/informationrealization.owl#realizes> <https://research.tib.eu/covid-19/data/entity/35136139>
<http://purl.org/net/provenance/ns#createdBy>
Anon_1   (more)
expand all